|
Thomas' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: FDA guidance could speed 505(b)(2) equivalence ratings, while BridgeBio exempts orphan drugs from its MFN pact and a pediatric gene therapy trial advances.
The top 10 stories from Wed Sep 2, 2026 06:59 AM to Thu Sep 3, 2026 06:59 AM
Generated September 3, 2026 at 6:59 AM
|
|
|
#1 Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era Published 2026-09-02 Biotech executives are adjusting pipeline sequencing, capital allocation, partnerships, and FDA engagement amid uncertainty from leadership changes, enforcement shifts, and evolving approval policies. Covered by: genengnews.com |
#2 CBER official overruled review team's rejection of new Replimune melanoma drug Published 2026-09-02 FDA official Asha Das overruled the agency’s review team to grant accelerated approval for Replimune’s melanoma treatment Tudriqev in early August, documents show. Covered by: endpoints.news, biospace.com |
#3 FDA leaders project enhanced scrutiny of foreign data Published 2026-09-02 FDA leaders are strengthening oversight of foreign clinical-trial data, amid concerns from lawmakers and industry about China’s expanding role in drug research. Covered by: endpoints.news, biospace.com |
#4 Updated US FDA Therapeutic Equivalence Guidance Allows Faster 505(b)(2) Rating Requests Published 2026-09-02 The FDA’s final therapeutic equivalence guidance may accelerate therapeutic-equivalence rating requests and automatic substitution for certain 505(b)(2) drugs. Covered by: insights.citeline.com |
#5 UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease Published 2026-09-02 uniQure filed applications seeking U.S. and UK approval for AMT-130, a gene therapy for Huntington’s disease; FDA priority review could enable approval in Q2 2027. Covered by: biospace.com |
#6 FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease Published 2026-09-02 The FDA allowed the first gene therapy clinical trial for children with ultra-rare Mucolipidosis Type IV, according to the ML4 Foundation. Covered by: prnewswire.com |
#7 Will Overton be a heat shield or a conduit for political and ideological influence? Published 2026-09-02 The commentary questions whether Will Overton will shield the FDA from political influence or enable it, arguing the choice could shape the agency’s future. Covered by: biocentury.com |
#8 BridgeBio’s MFN Pact Exempts Orphan Products, Highlighting Deals Bespoke Nature Published 2026-09-02 BridgeBio’s most-favored-nation agreement exempts orphan products, illustrating how pharmaceutical companies tailor such deals to their specific needs. Covered by: insights.citeline.com |
#9 Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals Published 2026-09-02 Novartis and Bristol Myers Squibb paused CAR-T trials over safety concerns, while Revolution Medicines gained early FDA approval for a pancreatic cancer drug and BioNTech halted an mRNA trial. Covered by: biospace.com, endpoints.news |
#10 Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC Published 2026-09-02 Norroy Bioscience received China’s NMPA clearance to initiate a pivotal Phase III trial of 177Lu-NYM032 for metastatic castration-resistant prostate cancer. Covered by: prnewswire.com |
